Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
TG4010
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (4)
Antineoplastic Agents
Cancer Vaccines
MVA-MUC1-IL2 Vaccine
Membrane Glycoproteins
Narrower (1)
MVA-MUC1-IL2
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
E. Quoix
,
F. Forget
,
+9 authors
J. Limacher
2015
Corpus ID: 78568258
3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A…
Expand
Review
2014
Review
2014
Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
R. Ruiz
,
B. Hunis
,
L. Raez
Current Oncology Reports
2014
Corpus ID: 29594342
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy…
Expand
2012
2012
TG4010
J. Limacher
,
E. Quoix
Oncoimmunology
2012
Corpus ID: 215524601
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as…
Expand
2012
2012
TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer…
E. Quoix
,
J. Nemunaitis
,
T. Burzykowski
,
B. Bastien
,
G. Lacoste
2012
Corpus ID: 202001847
TPS7610 Background: TG4010 is an immunotherapy product based on a poxvirus (MVA) coding for the MUC1 tumor-associated antigen and…
Expand
2011
2011
Immunotherapy: A first for first-line therapy in NSCLC
R. Kirk
Nature Reviews Clinical Oncology
2011
Corpus ID: 9005066
Chemotherapy is the standard of care for patients with advanced-stage non-small-cell lung cancer (NSCLC), and it is widely agreed…
Expand
2009
2009
Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.
B. Acres
,
E. Quoix
,
+7 authors
J. Bonnefoy
Journal of Clinical Oncology
2009
Corpus ID: 45993908
3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a…
Expand
2008
2008
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
R. Ramlau
,
V. Westeel
,
+7 authors
E. Quoix
2008
Corpus ID: 78636599
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1…
Expand
2007
2007
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
B. Acres
Journal of B.U.ON. : official journal of the…
2007
Corpus ID: 39603368
Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at…
Expand
2006
2006
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC).
E. Banu
,
O. Rixe
,
+7 authors
S. Oudard
Journal of Clinical Oncology
2006
Corpus ID: 25209849
2581 Background: MUC1 is a glycoprotein often over-expressed and underglycosylated in renal cell carcinoma (RCC) making it an…
Expand
Review
2004
Review
2004
MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data.
P. Squiban
,
T. Velu
,
+7 authors
E. Quoix
Journal of Clinical Oncology
2004
Corpus ID: 10323679
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required